Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis

Archives of Dermatology

Volumn 135, Issue 7, 1999, Pages 813-817

  Baggott, Joseph E ^a   Morgan, Sarah L ^a,b   Sams, W Mitchell ^c   Linden, Joel ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ADENOSINE; METHOTREXATE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; PURINE SYNTHESIS;

ADENOSINE; ADULT; AGED; AMINOIMIDAZOLE CARBOXAMIDE; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; MALE; METHOTREXATE; MIDDLE AGED; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PSORIASIS; RIBONUCLEOTIDES;

EID: 0032802514     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.135.7.813     Document Type: Article

References (26)

1. Gubner R. Effect of aminopterin on epithelial tissues. Arch Dermatol. 1951;64: 688-699.
2. Edmundson G, Guy W. Treatment of psoriasis with folic acid antagonists. Arch Dermatol. 1958;78:200-203.
3. Weinstein GD, Frost P. Methotrexate for psoriasis: a new therapeutic schedule. Arch Dermatol. 1971;103:33-38.
4. Roenigk HH Jr, Maibach HI, Weinstein GD. Use of methotrexate in psoriasis. Arch Dermatol. 1972;105:363-365.
5. Hanno R, Gruber GG, Owen LG, Callen JP. Methotrexate in psoriasis: a brief review of indications, usage, and complications of methotrexate therapy. J Am Acad Dermatol. 1980;2:171-174.
6. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19:145-156.
7. Collins P, Rogers S. The efficacy of methotrexate in psoriasis: a review of 40 cases. Clin Exp Dermatol. 1992;17:257-260.
8. Van Dooren-Greebe RJ, Kuipens ALA, Mulder J, de Boo T, Van de Kerkhof PCM. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130:204-210.
9. Luhby AL, Cooperman JM. Aminoimidazolecarboxamide excretion in vitamin-B12 and folic-acid deficiencies. Lancet. 1962;2:1381-1382.
10. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986;236: 193-200.
11. Ha T, Baggott JE. 5-aminoimidazole-4-carboxamide ribotide (AICAR) and its metabolites: metabolic and cytotoxic effects and accumulation during methotrexate treatment. J Nutr Biochem. 1994;5:522-528.
12. Baggott JE, Morgan SL, Ha TS, et al. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheum. 1993;11:101-105.
13. Baggott JE, Morgan SL, Koopman WJ. The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and urinary aminoimidazolecarboxamide excretion. Arthritis Rheum. 1998;41:1407-1410.
14. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675-2682.
15. Kredich NM, Hershfield MS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Vallee D, eds. The Metabolic Basis of Inherited Disease. Vol 1. 6th ed. New York, NY: McGraw-Hill Book Co: 1989;1045-1075.
16. Hirschorn R. Adenosine deaminase deficiency: molecular basis and recent developments. Clin Immunol Immunopathol. 1995;76(suppl):S219-S227.
17. Blackburn MR, Datta SK, Wakamiya M, Vartabedian BS, Kellems RE. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J Biol Chem. 1996;271:15203-15210.
18. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated inhibition of T-cell activation and expansion. Blood. 1997; 90:1600-1610.
19. McGeer PL, McGeer EG, Griffin MC. Excretion of 4-amino-5-imidazolecarboxamide in human urine. Can J Biochem Physiol. 1961;39:591-603.
20. Baggott JE, Johanning GL, Branham KE, et al. Cofactor role for 10-formyldihydrofolic acid. Biochem J. 1995;308:1031-1036.
21. Linden J, Taylor HE, Feldman MD, et al. The precise radioimmunoassay of adenosine: minimization of sample collection artifacts and immunocrossreactivity. Anal Biochem. 1992;201:246-254.
22. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:833-841.
23. Hirshhorn R, Rutech H, Rubinstein A, et al. Increased excretion of modified adenine nucleosides in children with adenosine deaminase deficiency. Pediatr Res. 1982;16:362-369.
24. Mills GC, Schmalstieg FC, Goldblum RM. Urinary excretion of modified purines and nucleosides in immunodeficient children. Biochem Med. 1985;34:37-51.
25. Herbert V, Streiff RH, Sullivan LN, McGeer PL. Deranged purine metabolism manifested by aminoimidazolecarboxamide excretion in megaloblastic anemia, hemolytic anemia and liver disease. Lancet. 1964;2:45-46.
26. Hendel J, Nyfors A. Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur J Clin Pharmacol. 1984;27:607-610.